A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

427

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

March 10, 2022

Conditions
Asthma
Interventions
DRUG

Fluticasone propionate/salmeterol (FS)

FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

DRUG

Albuterol

Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

DRUG

Standard of Care Asthma Medication

Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma

DRUG

Standard of Care Rescue Medication

Current rescue medication

Trial Locations (46)

11423

Teva Investigational Site 14956, Hollis

15241

Teva Investigational Site 14967, Pittsburgh

21162

Teva Investigational Site 14983, White Marsh

28054

Teva Investigational Site 14954, Gastonia

29420

Teva Investigational Site 14989, North Charleston

31406

Teva Investigational Site 14942, Savannah

33012

Teva Investigational Site 14984, Hialeah

33014

Teva Investigational Site 14960, Miami Lakes

33016

Teva Investigational Site 14979, Hialeah

33135

Teva Investigational Site 14953, Miami

33173

Teva Investigational Site 14944, Miami

33180

Teva Investigational Site 14943, Aventura

33189

Teva Investigational Site 14978, Cutler Bay

33216

Teva Investigational Site 14970, Miami

33308

Teva Investigational Site 14955, Fort Lauderdale

33472

Teva Investigational Site 14969, Boynton Beach

34239

Teva Investigational Site 14981, Sarasota

40509

Teva Investigational Site 14950, Lexington

42301

Teva Investigational Site 14949, Owensboro

43617

Teva Investigational Site 14968, Toledo

45221

Teva Investigational Site 14941, Cincinnati

48336

Teva Investigational Site 14964, Farmington Hills

60026

Teva Investigational Site 14961, Glenview

62704

Teva Investigational Site 14972, Springfield

68505

Teva Investigational Site 14977, Lincoln

73120

Teva Investigational Site 14952, Oklahoma City

Teva Investigational Site 14958, Oklahoma City

76712

Teva Investigational Site 14948, Waco

77081

Teva Investigational Site 14963, Houston

78006

Teva Investigational Site 14985, Boerne

80033

Teva Investigational Site 14962, Wheat Ridge

80907

Teva Investigational Site 14966, Colorado Springs

83706

Teva Investigational Site 14947, Boise

84020

Teva Investigational Site 14987, Draper

84107

Teva Investigational Site 14965, Murray

85018

Teva Investigational Site 14971, Phoenix

90025

Teva Investigational Site 14982, Los Angeles

92120

Teva Investigational Site 14945, San Diego

92123

Teva Investigational Site 14946, San Diego

92708

Teva Investigational Site 14974, Fountain Valley

33166-6817

Teva Investigational Site 14975, Miami

32308-4355

Teva Investigational Site 14951, Tallahassee

04401

Teva Investigational Site 14976, Bangor

68123-4303

Teva Investigational Site 14990, Bellevue

08755

Teva Investigational Site 14957, Toms River

02906

Teva Investigational Site 14988, Providence

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT04677959 - A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma | Biotech Hunter | Biotech Hunter